What might I pay?

For certain approved weight and diabetes drugs, cash offers from their makers were mostly $149–$499 a month on September 26, 2026.

The medicine and the amount of drug in each shot or pill affect the price.

Keeping the discount on some tirzepatide (Zepbound) and orforglipron (Foundayo) offers means refilling no later than 45 days after your last delivery.

Ask for the refill deadline for your offer and what you would pay if you miss it.

This is a medicine-price range, not a quote for every peptide or the full care bill.

Some insurance benefits start only after you have paid a set amount, called a deductible. Your out-of-pocket maximum caps your own spending each year on costs covered by the plan.

These cash payments go outside insurance, so they do not help you reach either of those limits.

A monthly online weight-care membership can cover the service while the medicine is billed separately.

Ask for visits, any membership, tests, medicine, shipping, and follow-up in the same quote. Ask what keeps being charged if treatment is not prescribed or if you stop.

Give the insurer the exact drug name and the reason it is proposed. Ask whether it is on the covered-drug list. Check whether prior authorization is needed: the plan must grant that approval before making payment. Ask what you would owe after that approval.

Part D is Medicare’s cover for prescription medicines.

Weight-loss use remains excluded under Medicare’s Part D drug benefit in the rules as of September 26, 2026.

The same drug may qualify for Part D payment when used for type 2 diabetes or certain heart risks instead of weight loss.

For example, semaglutide (Wegovy) may qualify to lower the risk of major heart or blood-vessel problems in people who already have heart disease and excess weight.

Your plan still checks its drug list and decides whether to approve payment for your use.

Ask your doctor which use fits your health, then ask your plan whether it covers that use.

The hormone called GLP-1 helps influence both blood sugar and appetite.

A separate program, Medicare’s temporary GLP-1 Bridge, covers selected products when a person qualifies.

Its monthly copay, the patient’s share of the cost, is $50.

The first program day is July 1, 2026, with December 31, 2027 marking the last.

The covered options checked September 26, 2026 are Foundayo (orforglipron), Wegovy (semaglutide, in tablet or shot form), and only the KwikPen form of Zepbound (tirzepatide).

Zepbound’s single-dose pens and small medicine bottles are not included.

You must have turned 18 to qualify under the September 26, 2026 rules. You also need separate Part D coverage for medicines, or Medicare Advantage coverage of the coordinated care type that includes a drug benefit.

If you have Medicare Advantage, ask your plan, “Is mine a coordinated care plan with drug cover that can use the Bridge?”

Private fee-for-service plans, cost-contract plans, and PACE plans do not qualify on their own; a separate Part D plan is needed.

These are names of Medicare plan types. Ask your plan which type you have.

You cannot enter the Bridge in 2026 if your Part D benefit has already paid for a GLP-1 drug that year.

BMI means body mass index: a number based on your weight and height. Ask your doctor to check your number and health record against these rules.

The rules below were checked September 26, 2026 and use your health when you first started GLP-1 treatment.

At 35 or above, your BMI meets the weight requirement on its own, with no other listed condition needed.

At a BMI of at least 30, one of these must also apply: the specified form of heart failure, high blood pressure that resists control, or kidney disease of stage 3a or a later stage.

The heart-failure diagnosis must say “preserved ejection fraction,” meaning the heart still squeezes out a normal share of its blood. Stage 3a is a kidney-disease level your doctor can check in your record.

For blood pressure to qualify, it must remain over 140 on the upper reading or over 90 on the lower reading even with two medicines for blood pressure.

At a BMI of at least 27, you need one added condition: pre-diabetes, a heart attack in your past, a stroke in your past, or artery disease causing symptoms in your limbs.

With pre-diabetes, blood sugar has risen past the normal range without reaching the diabetes threshold.

People with type 2 diabetes are excluded from the Bridge and instead go through the ordinary Part D coverage route.

The Bridge cannot be used for obstructive sleep apnea of moderate or severe intensity, a condition in which breathing gets blocked repeatedly while asleep.

A liver condition called MASH also rules it out when there is moderate to advanced scarring but not cirrhosis, the most severe scarring stage.

MASH is liver inflammation linked to fat buildup. That exact diagnosis matters; a general note saying “fatty liver” does not settle this check.

A prescription to reduce major heart or blood-vessel risks goes to the ordinary Part D plan instead.

A prescription and approval are required before the Bridge pays.

In 2026, the Bridge’s own central service checks requests for approval and handles pharmacy payments.

Alongside the prescription, there must be a continuing plan that addresses food and physical activity.

Ask your doctor to send the request and tell you whether it was approved. Check that answer before counting on this price.

For covered drugs under Part D, your own yearly spending is capped at $2,100 for 2026; the cap for 2027 is $2,400.

Your $50 Bridge payment stays outside that calculation, adding nothing toward the Part D cap.

No extra help for low incomes reduces that price, and coupons cannot be added.

December 31, 2026 is the expiry date for many starting prices and savings-card terms in the September 26, 2026 check.

Ask for the regular price and the offer’s end date. Check the price again when the offer ends.